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A 73-year-old male was referred with severe mitral
regurgitation 9 years after mitral valve annuloplasty
with a 32-mm Edwards Lifesciences ring. On the
basis of an anticipated high perioperative risk
related to chronic kidney disease and left ventricular
systolic dysfunction, mitral valve-in-ring implant-
ation using a 29-mm Edwards SAPIEN prosthesis
was performed by transapical access (Panel A). Post-
procedural three-dimensional transoesophageal
echocardiography revealed three paravalvular re-
gurgitation jets at the 3, 7, and the 11 o’clock posi-
tions (Panels B and C ).
In this patient, we observed a third type of regur-
gitation in Edwards SAPIEN prostheses, which is
caused by the device design. Edwards SAPIEN pros-
theses are built up by bovine pericardial tissue leaf-
lets fixed on a stainless steel frame. A polyethylene
terephthalate skirt partially covers the steel frame.
However, since the skirt covers the basal two-thirds
of the frame only, regurgitation through its uncov-
ered part may occur (arrow, Panel D; adapted
from www.edwards.com/products/transcathetervalve/
Pages/sapienthv.aspx). This type of regurgitation was seen in the patient presented here, since the skirt is positioned in the left
atrium rather than the annuloplasty ring. The commissures cover the whole length of the steel frame, and the regurgitation jets
are therefore located in between the commissures and positioned 1208 apart from each other. In patients with Edwards
SAPIEN prostheses in aortic position, the same phenomenon may be observed with prostheses implanted too apically. However,
as the left ventricular outflow tract is narrow, regurgitation jets are more difficult to visualize.
Hence, after Edwards SAPIEN prosthesis implantation, regurgitation is transvalvular or paravalvular or ‘supra-skirtal’. As the tech-
nology of transcatheter valves is still evolving, constant improvement in the device design and proper placement of the prosthesis are
important.
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